Prolonged illnesses like cancer and chronic infections often leave the immune system in a state of exhaustion, where its ...

Researchers found that bioengineered CAR-T cells when mixed with other immune cells can "donate" proteins, suggesting ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

After leading Japan’s largest drugmaker for 11 years, Takeda CEO Christophe Weber plans to step down in June of 2026. He will ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Weber said it is the right time to appoint a successor, given the company's "competitive growth outlook, new product launches expected from the second half of 2026 onwards, and the anticipated ...

Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of ...